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NEW APPROACHES IN THE TREATMENT OF HIGH-GRADE
INTRAEPITHELIAL LESIONS OF THE CERVIX
Introduction
In 2018, according to the latest GLOBOKAN data, 527,600 new cases of 
cervical cancer patients and 265,700 deaths were diagnosed 
worldwide. The most important risk factor is HPV infection. Treatment 
of HSIL lesions of the cervix associated with HPV may delay or prevent 
progression to cervical cancer. 
Purpose
The aim of this study is to evaluate surgical, antiviral and 
immunomodulatory treatment in patients with HSIL of the cervix. 
Material and methods
This is a prospective study of 26 patients with high-grade 
intraepithelial lesions of cervical malignancy (CIN II, CIN III, CIS) 
treated surgically, antivirally and immunomodulatory during the years 
2017-2020 in IMSP Oncological Institute of the Republic of Moldova.
Results
Case reports of patients which have been analysed ranged from 23 to 48 years 
old. The average age of the examined patients was 33 years. Patients with HSIL 
were treated surgically with LLETZ (89%) and total hysterectomy (11%). The 
postoperative histological result was CIN II-33%, CIN III-56% and CIS-11%. 
Antiviral therapy was administered to 28% of patients, antiviral and 
immunomodulatory therapy was administered to 88%, and 12% of patients did 
not receive any treatment. All patients were monitored by liquid-based 
cytology + HPV genotyping at 6 months, 88.46% were determined NILM with 
negative HPV, 11.54%- were determined LSIL + HPV positive insignicant load.
Conclusions
The treatment of high-grade neoplasms of the cervix is combined surgically, 
antiviral and immunomodulatory. At follow-up the cytology was NILM and HPV 
negative in 88.46% of patients, thus decreasing the risk of recurrence of the 
disease and a subsequent transformation to cervical carcinoma.
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